EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HDAC Inhibitors Enhance the Chemosensitivity of Osteosarcoma Cells to Etoposide by Suppressing the Hippo/YAP Signaling Pathway

Zhijie Cao iD, Yulu Chen, Mengshan Chen, Qianjin Fan, Hui Sun, Dong Jin, Yajing Liu iD, Yanwen Xiong iD, Donglai Wang

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26188935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Zhijie Cao und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China. Hauptthemen laut MEDLINE: Osteosarcoma, Etoposide, Histone Deacetylase Inhibitors, Signal Transduction. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteosarcoma primarily occurs in children and adolescents, and is a highly aggressive bone tumor, particularly presenting challenges in metastatic or recurrent cases due to chemoresistance. Emerging evidences suggest that histone deacetylase inhibitors (HDACis) may exert anti-tumor effects by enhancing the efficacy of various therapeutic modalities. However, the combination of traditional chemotherapy with HDACi-based treatment for osteosarcoma intervention has not been thoroughly explored. This study investigates the anticancer properties of HDACis and/or etoposide (VP16) on the osteosarcoma cell lines U2OS and SJSA-1. Cell viability, morphology, growth and apoptosis were evaluated after treatments, in addition to their influence on the expression levels of proteins associated with apoptotic processes. To elucidate the underlying mechanisms, we employed RNA sequencing, RT-qPCR, and Western blot analyses. Treatment with either HDACis or VP16 alone resulted in an antiproliferative effects in U2OS and SJSA-1 cell lines. Notably, HDACis significantly increased the sensitivity of osteosarcoma cells to VP16, as evidenced by marked differences in cell viability, growth, morphology and apoptosis. Furthermore, when compared to doxorubicin treatment, this VP16/TSA/NAM combinatory regimen demonstrated a comparable ability to suppress cell viability while exhibiting a more pronounced inhibition of cell proliferation. Mechanistically, the combination of HDACis and VP16 specifically resulted in inhibition of the Hippo/YAP signaling cascade, accompanied by a reduction in total YAP1 protein expression. Collectively, our findings suggest that HDACis potentiate the capacity of VP16 to hinder cellular proliferation and trigger apoptosis via the downregulation of the Hippo/YAP pathway, thereby providing a prospective approach to overcome chemoresistance in osteosarcoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaEtoposideHistone Deacetylase InhibitorsSignal TransductionBone NeoplasmsDrug Resistance, NeoplasmTranscription FactorsAdaptor Proteins, Signal TransducingProtein Serine-Threonine KinasesHumansHippo Signaling PathwayCell Line, TumorYAP-Signaling ProteinsApoptosisCell ProliferationCell SurvivalGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

HDAC inhibitoranti-tumorchemoresistancecombination therapyetoposideosteosarcoma

Substanzen

EtoposideHistone Deacetylase InhibitorsYAP-Signaling ProteinsYAP1 protein, humanTranscription FactorsAdaptor Proteins, Signal TransducingProtein Serine-Threonine Kinases

Autor:innen und Institutionen

  • National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
  • Institute of Public Health, School of Medicine, Nankai University, Tianjin 300071, China.
  • State Key Laboratory of Common Mechanism Research for Major Diseases & Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union M…

ORCID-Profile: Zhijie Cao, Yajing Liu, Yanwen Xiong

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Cao, Z., Chen, Y., Chen, M., Fan, Q., Sun, H., Jin, D., Liu, Y., Xiong, Y., & Wang, D. (2025). HDAC Inhibitors Enhance the Chemosensitivity of Osteosarcoma Cells to Etoposide by Suppressing the Hippo/YAP Signaling Pathway. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26188935

Vancouver

Cao Z, Chen Y, Chen M, Fan Q, Sun H, Jin D, et al. HDAC Inhibitors Enhance the Chemosensitivity of Osteosarcoma Cells to Etoposide by Suppressing the Hippo/YAP Signaling Pathway. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26188935

BibTeX
@article{Cao2025,
  author = {Cao, Zhijie and Chen, Yulu and Chen, Mengshan and Fan, Qianjin and Sun, Hui and Jin, Dong and Liu, Yajing and Xiong, Yanwen and Wang, Donglai},
  title = {HDAC Inhibitors Enhance the Chemosensitivity of Osteosarcoma Cells to Etoposide by Suppressing the Hippo/YAP Signaling Pathway},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26188935}
}
Kostenlos starten →